| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
INGELHEIM, Germany—Boehringer Ingelheim (BI) announced recently a strategic partnership with China’s Peking University (PKU) aimed at jointly advancing early science innovation across a range of areas of high medical need.
 
The partnership will implement a “multifaceted collaboration model that nimbly and flexibly caters for the specific needs of the involved research groups,” as BI puts it. It will comprise project-based research, a joint post-doctorate fellowship program and a number of Boehringer Ingelheim-endowed investigators. The partnership aims to strengthen BI’s portfolio of early and unique pipeline projects, “supporting the company’s aspiration to be at the forefront of science and technology and deliver more first-in-class medicines with breakthrough potential” and taking BI’s research and development efforts in Asia “to the next level.”
 
Research teams at PKU will work closely with their counterparts at Boehringer Ingelheim to leverage the company’s expertise in pharmaceutical research and development with their novel approaches and insights to identify novel targets and medicines within and beyond the company’s key therapeutic areas. These include cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and central nervous system diseases.
 
“We are excited to launch a comprehensive partnership program with scientists from PKU who are at the forefront of biomedical discovery. This collaboration with one of the most prestigious scientific institutions will enable us to benefit from and contribute to the impressive boom in life-science research in China,” said Dr. Clive R. Wood, senior corporate vice president of discovery research at BI. “The flexible partnership model developed allows PKU and Boehringer Ingelheim scientists to work hand in hand to jointly advance promising biomedical discoveries.”
 
Asia, and in particular China, has gained a reputation as a leading center of excellence in biomedical research, opening new collaborative opportunities for Boehringer Ingelheim to provide the next wave of medical innovation. The PKU collaboration continues the success of recent projects in China, such as the China Southeast University Institute of Life Sciences’ project with Boehringer Ingelheim to develop new treatment approaches for hearing loss through regeneration of hair cells.
 
“This new collaboration with Boehringer Ingelheim reflects a mutual goal for excellence and providing innovative approaches that bridge the gap between basic science and medical development,” said Jie Wang, vice president of Peking University. “We are proud to work with Boehringer Ingelheim to advance knowledge that will benefit patients in China and worldwide.”

Related Topics

Published In

Volume 13 - Issue 6 | June 2017

June 2017

June 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue